Urinary Tract Infection Market Research Report—Forecast till 2027

$4,450$6,250

Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection.

Clear

Description

Urinary Tract Infection Market Research Report—Forecast till 2027

Market Overview
Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection. The major causes of UTI infection are unsafe sex, lack of hygiene, and diabetes.
Global Urinary Tract Infections Market is expected to register the highest market growth owing to the largest market value of USD 9,490.88 Million in 2019. As per the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affect almost half the female population around the world. Urological health issues are more common in diabetic patients. An increasing prevalence of diabetic population is expected to boost the global UTI patients worldwide. However, complex regulatory requirements are anticipated to restrain the growth of the global urinary tract infection market during the review period.
Market Segmentation
Global Urinary Tract Infections Market has been segmented into Drug Class, Application, Pathogen, End User.
In terms of drug class, the market has been classified into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones segment is further sub-divided into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is again classified into avycaz, cedax, cefdinir, and cefditoren. The β-lactam is further divided into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.
The Global Urinary Tract Infections Market, based on application, has been divided into urethritis, cystitis, and pyelonephritis. In terms of the pathogen, the market has been categorized into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. By end-user category, the global urinary tract infections market has been classified into hospitals, clinics, self-administered, and others.
Regional Analysis
Geographically, the global UTI market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global market owing to the largest market share of 33.6% of the global market in 2019. The regional market growth is driven by the presence of key manufacturers, the increasing prevalence of urinary tract infections, and the increasing aging woman population in the region. The market in the Americas is categorized into North America and Latin America. Additionally, the global market growth is driven by the increasing technological advancements in diagnostics and therapeutic products coupled with the rising prevalence of urinary tract diseases and other kidney problems.
Europe is expected to register the second-largest market of the Global Urinary Tract Infection. The regional market is segmented into France, Germany, Italy, Spain, and the UK. The regional market growth is attributed to the increasing awareness of urinary tract diseases, increasing educational activity, and the availability of different diagnostic and therapeutic methods to manage the infection. Asia-Pacific is set to exhibit the fastest-growing market for UTI during the review period. The regional market growth is driven by the developing economies and highly populated countries such as China, India, and South Korea.
Major Players
The Prominent Players in the Global Urinary Tract Infections Market are Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVENESS ANALYSIS 18

2 MARKET INTRODUCTION
2.1 DEFINITION 19

2.2 SCOPE OF THE STUDY 19

2.3 RESEARCH OBJECTIVE 19

2.4 MARKET STRUCTURE 19

2.5 ASSUMPTIONS & LIMITATIONS 20

3 RESEARCH METHODOLOGY
3.1 DATA MINING 21

3.2 SECONDARY RESEARCH 22

3.3 PRIMARY RESEARCH 23

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 25

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26

3.6.1 BOTTOM-UP APPROACH 27

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 28

3.8 VALIDATION 28

4 MARKET DYNAMICS
4.1 OVERVIEW 29

4.2 DRIVERS 30

4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30

4.2.2 LAUNCH OF COMBINATION DRUGS 30

4.3 RESTRAINTS 31

4.3.1 COMPLEX REGULATORY REQUIREMENTS 31

4.4 OPPORTUNITIES 32

4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 33

5.1.1 R&D AND DESIGNING 34

5.1.2 MANUFACTURING 34

5.1.3 DISTRIBUTION & SALES 34

5.1.4 POST-SALES SERVICES 34

5.2 PORTER’S FIVE FORCES MODEL 35

5.2.1 BARGAINING POWER OF SUPPLIERS 36

5.2.2 BARGAINING POWER OF BUYERS 36

5.2.3 THREAT OF NEW ENTRANTS 36

5.2.4 THREAT OF SUBSTITUTES 36

5.2.5 RIVALRY 36

5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37

5.3.1 OVERVIEW 37

5.3.2 IMPACT ON SUPPLY CHAIN 37

5.3.3 IMPACT ON PRODUCTION 38

6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS
6.1 OVERVIEW 40

6.2 QUINOLONES 42

6.3 Β-LACTAM & CEPHALOSPORINS 43

6.4 AMINOGLYCOSIDES 44

6.5 PENICILLIN 44

6.6 AZOLES 45

7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION
7.1 OVERVIEW 46

7.2 URETHRITIS 47

7.3 CYSTITIS 48

7.4 PYELONEPHRITIS 48

8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN
8.1 OVERVIEW 49

8.2 ESCHERICHIA COLI 50

8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51

8.4 KLEBSIELLA PNEUMONIAE 51

8.5 PROTEUS MIRABILIS 52

8.6 ENTEROCOCCUS FAECALIS 52

9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER
9.1 OVERVIEW 53

9.2 HOSPITALS 54

9.3 CLINICS 54

9.4 SELF-ADMINISTERED 55

10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION
10.1 OVERVIEW 56

10.2 AMERICAS 58

10.2.1 NORTH AMERICA 61

10.2.1.1 US 64

10.2.1.2 CANADA 67

10.2.2 LATIN AMERICA 70

10.3 EUROPE 73

10.3.1 WESTERN EUROPE 76

10.3.1.1 GERMANY 80

10.3.1.2 FRANCE 83

10.3.1.3 UK 86

10.3.1.4 ITALY 89

10.3.1.5 SPAIN 92

10.3.1.6 REST OF WESTERN EUROPE 95

10.3.2 EASTERN EUROPE 98

10.4 ASIA-PACIFIC 101

10.4.1 CHINA 105

10.4.2 INDIA 108

10.4.3 JAPAN 111

10.4.4 AUSTRALIA 114

10.4.5 SOUTH KOREA 117

10.4.6 REST OF ASIA-PACIFIC 120

10.5 MIDDLE EAST & AFRICA 123

10.5.1 MIDDLE EAST 126

10.5.2 AFRICA 129

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW 132

11.2 COMPETITIVE BENCHMARKING 133

11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2019 134

11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134

11.4.1 PRODUCT APPROVALS AND LAUNCHES 134

11.4.2 ACQUISITIONS 134

11.5 FINANCIAL MATRIX 135

12 COMPANY PROFILES
12.1 PFIZER INC. 136

12.1.1 COMPANY OVERVIEW 136

12.1.2 FINANCIAL OVERVIEW 137

12.1.3 PRODUCTS/SERVICES OFFERED 138

12.1.4 KEY DEVELOPMENTS 138

12.1.5 SWOT ANALYSIS 138

12.1.6 KEY STRATEGIES 139

12.2 NOVO NORDISK A/S 140

12.2.1 COMPANY OVERVIEW 140

12.2.2 FINANCIAL OVERVIEW 140

12.2.3 PRODUCTS/SERVICES OFFERED 141

12.2.4 KEY DEVELOPMENTS 141

12.2.5 SWOT ANALYSIS 141

12.2.6 KEY STRATEGIES 141

12.3 NOVARTIS AG 142

12.3.1 COMPANY OVERVIEW 142

12.3.2 FINANCIAL OVERVIEW 142

12.3.3 PRODUCTS/SERVICES OFFERED 143

12.3.4 KEY DEVELOPMENTS 143

12.3.5 SWOT ANALYSIS 143

12.3.6 KEY STRATEGIES 144

12.4 MERCK & CO., INC. 145

12.4.1 COMPANY OVERVIEW 145

12.4.2 FINANCIAL OVERVIEW 145

12.4.3 PRODUCTS/SERVICES OFFERED 146

12.4.4 KEY DEVELOPMENTS 146

12.4.5 SWOT ANALYSIS 146

12.4.6 KEY STRATEGIES 146

12.5 ELI LILY AND COMPANY 147

12.5.1 COMPANY OVERVIEW 147

12.5.2 FINANCIAL OVERVIEW 147

12.5.3 PRODUCTS/SERVICES OFFERED 148

12.5.4 KEY DEVELOPMENTS 148

12.5.5 SWOT ANALYSIS 148

12.5.6 KEY STRATEGIES 148

12.6 ALLERGAN 149

12.6.1 COMPANY OVERVIEW 149

12.6.2 FINANCIAL OVERVIEW 149

12.6.3 PRODUCTS/SERVICES OFFERED 150

12.6.4 KEY DEVELOPMENTS 150

12.6.5 SWOT ANALYSIS 150

12.6.6 KEY STRATEGIES 150

12.7 CIPLA INC. 151

12.7.1 COMPANY OVERVIEW 151

12.7.2 FINANCIAL OVERVIEW 151

12.7.3 PRODUCTS/SERVICES OFFERED 151

12.7.4 KEY DEVELOPMENTS 151

12.7.5 SWOT ANALYSIS 152

12.7.6 KEY STRATEGIES 152

12.8 TEVA PHARMACEUTICALS 153

12.8.1 COMPANY OVERVIEW 153

12.8.2 FINANCIAL OVERVIEW 153

12.8.3 PRODUCTS/SERVICES OFFERED 154

12.8.4 KEY DEVELOPMENTS 154

12.8.5 SWOT ANALYSIS 154

12.8.6 KEY STRATEGIES 155

12.9 GLAXOSMITHKLINE PLC 156

12.9.1 COMPANY OVERVIEW 156

12.9.2 FINANCIAL OVERVIEW 156

12.9.3 PRODUCTS/SERVICES OFFERED 157

12.9.4 KEY DEVELOPMENTS 157

12.9.5 SWOT ANALYSIS 157

12.9.6 KEY STRATEGIES 157

12.10 BAYER AG 158

12.10.1 COMPANY OVERVIEW 158

12.10.2 COMPANY VALUE 158

12.10.3 FINANCIAL OVERVIEW 159

12.10.4 PRODUCTS/SERVICES OFFERED 159

12.10.5 KEY DEVELOPMENTS 159

12.10.6 SWOT ANALYSIS 160

12.10.7 KEY STRATEGIES 160

13 APPENDIX
13.1 REFERENCES 161

13.2 RELATED REPORTS 161